Coronary Computed Tomographic Angiography in Emergency Department Chest Pain Patients at Intermediate Risk of Acute Coronary Syndrome (CCTA)

November 19, 2007 updated by: Vancouver General Hospital
The purpose of this study is to determine whether Coronary Computed Tomographic Angiography (CCTA) will increase patient safety by decreasing the rate of missed ACS and adverse events in patients who receive standard care plus CCTA versus standard care alone. Additional goals of the study are to determine whether CCTA can safely reduce the duration of ED visits and the number and duration of hospital admissions.

Study Overview

Detailed Description

Justification:

Acute coronary syndrome (ACS) is the clinical manifestation of acute myocardial ischemia induced by coronary artery disease (CAD). Although most patients presenting with chest pain to the Emergency Department (ED) can be stratified into "high risk" or "low risk" chest pain algorithms, patients at "intermediate risk" are more difficult to manage. This translates into lengthy waits in the ED and repetitive investigations while 5.3% of cases of ACS are still missed and too many patients are admitted to the CCU (false positive rate of 14%). CCTA is a novel, non-invasive method for evaluating coronary artery stenosis and occlusion.

The ability to accurately diagnose or exclude ACS in patients in a rapid, non-invasive fashion has been previously lacking. If CCTA is shown to be clinically useful in risk stratification of this patient population, there is great potential for increasing patient safety, reducing ED admission times and decreasing the number and duration of CCU admission.

Objectives:

ED admission and discharge times, CCU consult and decision times and duration of CCU admission, cardiac risk factors, vital signs, laboratory results, ED disposition plan, CCTA results, coronary calcium score, index hospitalization diagnosis, investigations, revascularization rates as well as 30-day diagnosis, death, adverse event rate and subsequent investigations.

Research Method:

The study population will consist of ED chest pain patients at intermediate risk of ACS. Informed consent will be obtained for both CCTA and the 30-day follow up. Patients will be randomized into one of two diagnostic arms: standard care plus CCTA versus standard care alone. If the patient receives CCTA, the test will be interpreted by a blinded radiologist and the results provided to the ED physician and entered into the patient chart. A research nurse will collect workflow and clinical data for all enrolled patients.

Two reviewers, an ED physician and a cardiologist, blinded to the CCTA results, will independently review the index and 30 day clinical data. One of the following will be assigned: acute myocardial infarction, definite unstable angina, possible unstable angina, or no acute coronary syndrome. Alternate non-ACS diagnoses will be ascertained when applicable.

Statistical Analysis This proposal represents a pilot study to demonstrate the feasibility of identifying and recruiting patients to the trial, demonstrate the feasibility of collecting follow-up data, and provide preliminary estimates of outcome measures to help determine the sample size required for a definitive study. All analyses will be descriptive. Recruitment, crossover, follow-up, and completion rates will be determined. Estimates of diagnostic accuracy and length of stay in the ED will be determined and will be used to inform the design of the definitive study.

Study Type

Interventional

Enrollment (Anticipated)

150

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z1M9
        • Recruiting
        • VGH
        • Contact:
        • Sub-Investigator:
          • James KH Woo, MD BSc
        • Sub-Investigator:
          • Savvas Nicolaou, MD
        • Sub-Investigator:
          • Doug McKnight, MD
        • Sub-Investigator:
          • John Mayo, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria (all of the following):

  • Anterior or lateral chest pain
  • 19 years of age or older
  • Fixed address in British Columbia
  • Available for telephone follow-up

Exclusion criteria (any of the following).

  • Low Risk for ACS (all of the following):
  • Age < 40 years with normal ECG (T wave flattening is the only acceptable abnormality)
  • No prior history of ischemic chest pain (defined as a past diagnosis of MI or angina, previously prescribed nitroglycerine or a clear history of effort related angina)
  • High Risk for ACS (any of the following):
  • Diagnosis consistent with ST elevation myocardial infarction
  • New ST depression ≥ 0.05 mV
  • Troponin > 0.1
  • Patients with Killip class III or IV heart failure.
  • Hemodynamic instability
  • Previous enrolment in this study.
  • Presence of terminal noncardiac illness.
  • History of angioplasty with stenting and/or grafts.
  • Presence of atrial fibrillation.
  • Contraindication to administration of iodinated contrast agent.
  • Contraindication to beta-blocker administration (eg, asthmatics) AND calcium channel blocker administration.
  • Glomerular filtration rate less than 60 mL/min.
  • Previous ECG-gated CT with calcium score >1000 Agatston Units.
  • Pregnancy.
  • Patients with communication difficulties.
  • Patients who have a clear alternative diagnosis other than ischemic chest pain (e.g. traumatic chest pain or pneumonia).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control
Experimental: intervention
Receives CCTA
CCTA will be performed

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Emergency Department Admission Time
Time Frame: During initial presentation to hospital
During initial presentation to hospital

Secondary Outcome Measures

Outcome Measure
Time Frame
CCU consult time
Time Frame: During initial presentation to hospital
During initial presentation to hospital
CCU decision time
Time Frame: During initial presentation to hospital
During initial presentation to hospital
Duration of CCU admission
Time Frame: During initial presentation to hospital
During initial presentation to hospital
Adverse event rate
Time Frame: 30 days post ED visit
30 days post ED visit
All-cause mortality
Time Frame: 30 days post-ED visit
30 days post-ED visit

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: William F Dick, MD, Vancouver General Hospital
  • Study Director: John Mayo, MD, Vancouver General Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2007

Study Completion (Anticipated)

July 1, 2008

Study Registration Dates

First Submitted

May 15, 2007

First Submitted That Met QC Criteria

May 15, 2007

First Posted (Estimate)

May 16, 2007

Study Record Updates

Last Update Posted (Estimate)

November 20, 2007

Last Update Submitted That Met QC Criteria

November 19, 2007

Last Verified

November 1, 2007

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe